Blood: AFM13 United Pym monotherapy recurrent/incurable Hodgkin's lymphoma.

Center point: AFM13 is a dual-specific terephthal congenital cell bridge that activates NK cells and macrophages via CD16A to target CD30-plus lymphoma cells;
Summary: In recurrent/incurable Hodgkin's lymphoma (R/R HL), immunotherapy (e.g. PD-1 inhibitor Pymmama) has shown the efficacy of monotherapy and plays an increasingly important role in treatment.
CD30/CD16A Dual Specific Antibody AFM13 is a congenital immunocell joint, a first-class tepid antibody designed to bridge the gap between CD30 on HL cells and CD16A receptors on NK cells and macrophages to induce tumor cell killing.
studies of AFM13 have shown that for R/R HL patients, AFM13 single-drug therapy has a certain amount, and the combined AFM13 and Pymm monotherapy represents a reasonable new treatment.
a new study published recently in Blood, Bartlett et al. reported the results of an incremental study evaluating phase 1b doses in patients with AFM13 combined Pym monotherapy R/R HL.
main purpose of the study was to identify maximum tolerable doses (MTDs), and the secondary objective was to assess the safety, tolerability, anti-tumor activity, pharmacogenics and pharmacogenics of the joint programme.
in patients who have been treated many times in the past, AFM13 combined pym monotherapy is generally better tolerated and has similar safety characteristics compared to the known characteristics used separately for each drug.
the maximum therapeutic dose, the objective remission rate of AFM13 combined Pym monotherapy reached 88%, and the overall remission rate was 83%.
the combined treatment, AFM13's pharmacological dynamics assessment showed a half-life of up to 20.6 hours.
, the treatment is expected to be a new combination of immunotherapy for such patients.
.